These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 39180549)

  • 1. Continuous exposure to doxorubicin induces stem cell-like characteristics and plasticity in MDA-MB-231 breast cancer cells identified with the SORE6 reporter.
    Salinas-Jazmín N; Medina-Mondragón MA; Jiménez-López J; Guerrero-Rodríguez SL; Cuautle-Rodríguez P; Velasco-Velázquez MA
    Cancer Chemother Pharmacol; 2024 Oct; 94(4):571-583. PubMed ID: 39180549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
    Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y
    Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standard chemotherapy impacts on in vitro cellular heterogeneity in spheroids enriched with cancer stem cells (CSCs) derived from triple-negative breast cancer cell line.
    Moreira MP; Franco EP; Barros BAF; Anjos BRD; Almada DG; Barbosa INT; Braga LDC; Cassali GD; Silva LM
    Biochem Biophys Res Commun; 2024 Nov; 734():150765. PubMed ID: 39357337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxorubicin-Resistant TNBC Cells Exhibit Rapid Growth with Cancer Stem Cell-like Properties and EMT Phenotype, Which Can Be Transferred to Parental Cells through Autocrine Signaling.
    Paramanantham A; Jung EJ; Kim HJ; Jeong BK; Jung JM; Kim GS; Chan HS; Lee WS
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A live single-cell reporter system reveals drug-induced plasticity of a cancer stem cell-like population in cholangiocarcinoma.
    Kongtanawanich K; Prasopporn S; Jamnongsong S; Thongsin N; Payungwong T; Okada S; Hokland M; Wattanapanitch M; Jirawatnotai S
    Sci Rep; 2024 Sep; 14(1):22619. PubMed ID: 39349745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of stem cells-related signaling pathways in response to doxorubicin treatment in Hs578T triple-negative breast cancer cells.
    Tudoran O; Soritau O; Balacescu L; Visan S; Barbos O; Cojocneanu-Petric R; Balacescu O; Berindan-Neagoe I
    Mol Cell Biochem; 2015 Nov; 409(1-2):163-76. PubMed ID: 26187676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase (HDAC) inhibitors and doxorubicin combinations target both breast cancer stem cells and non-stem breast cancer cells simultaneously.
    Hii LW; Chung FF; Soo JS; Tan BS; Mai CW; Leong CO
    Breast Cancer Res Treat; 2020 Feb; 179(3):615-629. PubMed ID: 31784862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exosome-sheathed porous silica nanoparticle-mediated co-delivery of 3,3'-diindolylmethane and doxorubicin attenuates cancer stem cell-driven EMT in triple negative breast cancer.
    Sarkar R; Biswas S; Ghosh R; Samanta P; Pakhira S; Mondal M; Dutta Gupta Y; Bhandary S; Saha P; Bhowmik A; Hajra S
    J Nanobiotechnology; 2024 May; 22(1):285. PubMed ID: 38796426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pranlukast Antagonizes CD49f and Reduces Stemness in Triple-Negative Breast Cancer Cells.
    Velázquez-Quesada I; Ruiz-Moreno AJ; Casique-Aguirre D; Aguirre-Alvarado C; Cortés-Mendoza F; de la Fuente-Granada M; García-Pérez C; Pérez-Tapia SM; González-Arenas A; Segura-Cabrera A; Velasco-Velázquez MA
    Drug Des Devel Ther; 2020; 14():1799-1811. PubMed ID: 32494122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination.
    Fonseca NA; Rodrigues AS; Rodrigues-Santos P; Alves V; Gregório AC; Valério-Fernandes Â; Gomes-da-Silva LC; Rosa MS; Moura V; Ramalho-Santos J; Simões S; Moreira JN
    Biomaterials; 2015 Nov; 69():76-88. PubMed ID: 26283155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced efficacy of chemotherapy for breast cancer stem cells by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense.
    Sun M; Yang C; Zheng J; Wang M; Chen M; Le DQS; Kjems J; Bünger CE
    Acta Biomater; 2015 Dec; 28():171-182. PubMed ID: 26415776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eradication of cancer stem cells in triple negative breast cancer using doxorubicin/pluronic polymeric micelles.
    Zhao Y; Alakhova DY; Zhao X; Band V; Batrakova EV; Kabanov AV
    Nanomedicine; 2020 Feb; 24():102124. PubMed ID: 31756533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultrasound reverses chemoresistance in breast cancer stem cell like cells by altering ABCG2 expression.
    Guo L; Zheng P; Fan H; Wang H; Xu W; Zhou W
    Biosci Rep; 2017 Dec; 37(6):. PubMed ID: 28935760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4.
    McClements L; Annett S; Yakkundi A; O'Rourke M; Valentine A; Moustafa N; Alqudah A; Simões BM; Furlong F; Short A; McIntosh SA; McCarthy HO; Clarke RB; Robson T
    BMC Cancer; 2019 Apr; 19(1):351. PubMed ID: 30975104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
    Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
    Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of SOX2 expression delineates an end-point for paclitaxel-effectiveness in breast cancer stem cells.
    Mukherjee P; Gupta A; Chattopadhyay D; Chatterji U
    Sci Rep; 2017 Aug; 7(1):9170. PubMed ID: 28835684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-Eradication of Breast Cancer Cells and Cancer Stem Cells by Cross-Linked Multilamellar Liposomes Enhances Tumor Treatment.
    Kim YJ; Liu Y; Li S; Rohrs J; Zhang R; Zhang X; Wang P
    Mol Pharm; 2015 Aug; 12(8):2811-22. PubMed ID: 26098197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing chemosensitivity of wild-type and drug-resistant MDA-MB-231 triple-negative breast cancer cell line to doxorubicin by silencing of STAT 3, Notch-1, and β-catenin genes.
    Alkaraki A; Alshaer W; Wehaibi S; Gharaibeh L; Abuarqoub D; Alqudah DA; Al-Azzawi H; Zureigat H; Souleiman M; Awidi A
    Breast Cancer; 2020 Sep; 27(5):989-998. PubMed ID: 32328816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FSTL1 enhances chemoresistance and maintains stemness in breast cancer cells via integrin β3/Wnt signaling under miR-137 regulation.
    Cheng S; Huang Y; Lou C; He Y; Zhang Y; Zhang Q
    Cancer Biol Ther; 2019; 20(3):328-337. PubMed ID: 30336071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ursolic Acid Enhances Cytotoxicity of Doxorubicin-Resistant Triple-Negative Breast Cancer Cells via
    Lu Q; Chen W; Ji Y; Liu Y; Xue X
    Cancer Biother Radiopharm; 2022 Oct; 37(8):673-683. PubMed ID: 33493421
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.